Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

3 years ago

NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and…

Codexis and seqWell Announce Strategic Investment and Partnership Initiation

3 years ago

seqWell raises $7M Series C funding, led by CodexisCurrent investors Research Corporation Technologies and BroadOak Capital Partners also participated in…

MS Million Dollar Tower Challenge Aims to Raise $4m for MS Research by Sending More Than 140 Donors Rappelling Off Toronto Office Tower

3 years ago

Photo of 700 University Avenue, Toronto Photo of 700 University Avenue, TorontoTORONTO, April 21, 2022 (GLOBE NEWSWIRE) -- The Multiple…

Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics

3 years ago

Strengthens Management Team and Positions the Company for Growth and Expansion  New York, NY, and Tel Aviv, ISRAEL, April 21,…

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update

3 years ago

WARMINSTER, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…

Alignment Healthcare to Announce First Quarter 2022 Financial Results and Host Conference Call Thursday, May 5, 2022

3 years ago

ORANGE, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled…

InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

3 years ago

Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDVVANCOUVER, British…

Chalice Brands Ltd. Announces Execution of Definitive Agreements to Acquire Oregon Retail Stores and Cultivation Assets

3 years ago

PORTLAND, Ore., April 21, 2022 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (“Chalice” or the “Company”), a…

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer

3 years ago

Overall response rate (ORR) of 43% and median duration of response of 6 months seen with navicixizumab-paclitaxel combination in heavily…

Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines

3 years ago

Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and…